Hi Carol:
Glad to see that someone is keeping eye on third-tire bts. Hope *leader* will return to *this* board.
As Rick was, I was also holder of CTII, significant amount. Unfortunately, after learned about problems with encapsulated-cell technology (indications are neurodegenerative disorders and CNS pain) I reduced my holding to minimum. It appears that they are slowly fixing this initial problems in pain program, increased financial support from primary partner, Asta AB.
Nevertheless, GNE (neurodegenerative disorders: Parkinson's, ALS, ..) canceled collaboration on one of their cells-implant program. Several weeks ago, two insider bought company shares on open market, which ignite again my interest on this company. So, I bought additional small quantity.
Latest news on neural stem/progenitor cells catch me with surprise. :)
This are embryonic precursor cells which proliferate/differentiate under certain environment and in presence CNS grow factors in to specific but many different CNN cells.
Their results with transplant neuronal progenitor cells to the adult rat brain seam very real. CTII is not the only one who is doing this work, but their results in rats are most advance to my knowledge. Applications of this technology (if it prove to be successful in human, btw which is still long way to go) are enormous. Recently, scientists prove for first time that neuron cells can regenerate/new cells and substitute dead ones in their function. Transplantation of the precursorneuronal cells will significantly accelerate this process and return brain function in to acceptable level, at least in some degenerative disorders.
The problem is that this (CTII experiments) are EMBRYONIC forebrain cells. I guess they are working on solution to this ethical and human problems, similarly what is ACT doing.
All in all, news triggered interest to this forgotten company. It is not my very favor type company, but for now I intend to keep my position.
Miljenko
|
